Absci Co. (NASDAQ:ABSI) Stock Holdings Lifted by Two Sigma Advisers LP

Two Sigma Advisers LP raised its position in Absci Co. (NASDAQ:ABSI - Free Report) by 191.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 676,400 shares of the company's stock after purchasing an additional 444,700 shares during the quarter. Two Sigma Advisers LP owned about 0.59% of Absci worth $1,772,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. BNP Paribas Financial Markets bought a new stake in Absci during the fourth quarter worth approximately $28,000. Verdence Capital Advisors LLC acquired a new stake in shares of Absci in the fourth quarter valued at $37,000. Mariner LLC bought a new position in Absci during the fourth quarter valued at about $62,000. China Universal Asset Management Co. Ltd. bought a new position in Absci during the fourth quarter valued at about $64,000. Finally, Price T Rowe Associates Inc. MD grew its holdings in Absci by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,333 shares of the company's stock worth $77,000 after acquiring an additional 3,747 shares during the period. Institutional investors and hedge funds own 52.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ABSI shares. Wall Street Zen lowered shares of Absci from a "hold" rating to a "sell" rating in a research report on Friday. Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 target price on shares of Absci in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Absci in a research report on Wednesday, March 19th. KeyCorp lifted their price target on Absci from $5.00 to $9.00 and gave the stock an "overweight" rating in a research note on Wednesday, April 16th. Finally, Guggenheim reaffirmed a "buy" rating and set a $10.00 price objective on shares of Absci in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, Absci presently has an average rating of "Moderate Buy" and an average price target of $8.40.

Absci Stock Up 1.8%

Shares of ABSI stock traded up $0.05 on Tuesday, reaching $2.78. 1,551,439 shares of the company's stock traded hands, compared to its average volume of 2,755,914. The company has a market capitalization of $354.61 million, a P/E ratio of -2.99 and a beta of 2.19. Absci Co. has a 12-month low of $2.01 and a 12-month high of $6.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.63 and a current ratio of 5.63. The business's 50 day moving average price is $2.79 and its two-hundred day moving average price is $3.24.

Absci (NASDAQ:ABSI - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analysts' expectations of $1.07 million. Absci had a negative return on equity of 46.56% and a negative net margin of 2,321.56%. On average, equities analysts forecast that Absci Co. will post -0.89 earnings per share for the current year.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.